H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics today and set a price target of $120.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors including the promising results from Cytokinetics’ Phase 3 MAPLE-HCM trial. The trial demonstrated that aficamten significantly improves exercise performance in patients with obstructive hypertrophic cardiomyopathy (oHCM) compared to metoprolol. These results were presented at the Heart Failure Society of America Annual Scientific Meeting 2025, highlighting aficamten’s efficacy across various exercise performance measures.
Furthermore, the supplemental analyses on cardiopulmonary exercise testing (CPET) provided objective assessments of exercise stages, showing aficamten-mediated improvements in both submaximal and maximal exercise performance. These findings suggest a superior effect of aficamten over metoprolol, supporting its potential as a more effective treatment option for oHCM patients. These positive clinical outcomes, coupled with the company’s financial strategy, underpin Pantginis’s optimistic outlook on Cytokinetics’ stock.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $96.00 price target.
Based on the recent corporate insider activity of 147 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CYTK in relation to earlier this year.